lidERA - Trialing a new oral hormone receptor blocker in estrogen receptor positive breast cancer

Estrogen receptor (ER)-positive, HER2-negative breast cancer

Surgical removal of tumor

The purpose of this study is to compare the effects, good or bad, of giredestrant versus an approved endocrine therapy (a treatment that blocks or removes hormones), on patients with your type of cancer. Giredestrant is an experimental treatment, which means this new drug is being investigated to treat your type of cancer, but it has not been approved by health authorities including the Therapeutic Goods Administration (TGA) in Australia for cancer treatment or treatment of any other disease.

Giredestrant is designed to block the sex hormone called estrogen that contributes to your cancer's growth.

In this study, you will get either giredestrant or a drug chosen specifically for you by your study doctor. You can participate in this study based on your breast cancer characteristics, your current condition and how well you tolerated previous anti -cancer therapies.

Trial Status
Trial Phase
Phase 3 Drug Trial
Trial contact details
Contact Person
Donna Harvey
What you need to know

Who can take part?

  • Patients with early breast cancer who have had complete surgical removal of their tumor.


  • Patients with active cardiac disease, a history of blood clots or advanced cancer

What is involved for you?

  • Monthly visits for the first three months, then 3 monthly visits for the duration of the trial
  • Blood tests at each visit
  • Bone density scan every two years while on trial
  • Tumor assessment via CT/ PET/MRI scan as needed
  • Mammograms yearly
  • Physical exams, vital signs, ECG and health questionnaires at each visit
  • Treatment for at least five years and long term follow up for at least five years

Trial dates

This trial is accepting participants.

All research clinical trials news

Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.



Mater launches trial of Australian-first flu vaccine

Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...



Stephanie Guilas is improving outcomes for mums and bubs through research

Working as a research assistant in an immunology research lab, Yvonne Gautam learnt what a clinical trial was after being asked to set up a lab for a Phase Two clinical trial.



Clinical Trials Coordinator Yvonne Gautam is working towards creating better treatments for patients with diabetes

Displaying results 1-3 (of 16)
 |<  < 1 - 2 - 3 - 4 - 5 - 6  >  >|